COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01316185
Recruitment Status : Terminated (the enrollment was slow and never completed.)
First Posted : March 16, 2011
Last Update Posted : August 8, 2016
Information provided by (Responsible Party):
Eiger BioPharmaceuticals

Brief Summary:
The purpose of this study is to assess the optimal dose of EBP921 by comparing the efficacy and safety of 2 dose regimens in patients with chronic HDV.

Condition or disease Intervention/treatment Phase
Hepatitis D Drug: EBP921 Phase 1

Detailed Description:
This is an open-label, phase 1b, proof-of-concept study to assess the safety and efficacy of EBP921, a prenylation inhibitor, in subjects chronically infected with delta hepatitis. Subjects will be randomized to receive one of two different doses of EBP921. Dosing will occur over 28-days and during that time, evidence of antiviral response will be assessed by frequent measurements of HDV-RNA via PCR assay. In addition, safety lab data will also be collected along with surveillance monitoring of HBV activity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Dose-ranging Proof-of-concept Study Assessing the Safety and Efficacy of EBP921 in Therapy-naive Patients Chronically Infected With Delta Hepatitis (HDV)
Study Start Date : January 2011
Actual Primary Completion Date : April 2013
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Group 1
Low Dose for 28 days: n=4
Drug: EBP921
Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.

Experimental: Group 2
High Dose for 28 days; n=4
Drug: EBP921
Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.

Primary Outcome Measures :
  1. Change in HDV-RNA [ Time Frame: 28 days ]
    The primary efficacy endpoint will be the median change in HDV-RNA from baseline to HDV RNA nadir as measured by quantitative PCR during the 28-day dosing period.

Secondary Outcome Measures :
  1. Change in HDV RNA from baseline to Day 7, 14, 28 and post therapy weeks 1,2,4,8 [ Time Frame: 8 Weeks ]
    The median change in HDV RNA from baseline to Days 7, 14, 28, and post-therapy Weeks 1, 2, 4, and 8 of the study; the proportion of patients with alanine aminotransferase (ALT) normalization defined as ALT ≤ upper limit of normal for patients with ALT > ULN at baseline; assessment of peripheral blood mononuclear cell (PBMC) proliferation after 14 and 28 days exposure to EBP921; the percentage of patients with undetectable HDV RNA at Days 7, 14, 28, post-therapy Weeks 1, 2, 4, and 8; the median change in HBV DNA at Days 7, 14, 21, 28, 35, and 42, and HBsAg at Days 14, 28, and 42.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men and women age 18 or older with the capacity to give written informed consent
  2. Patients with compensated chronic HDV infection as indicated by presence of anti-HDV in serum.
  3. Liver biopsy should be performed within one-year of study screening and graded using the Knodell scoring system.
  4. Presence of HDV antigen in liver tissue or HDV-RNA in serum.
  5. Active HBV replication will not exclude patients.
  6. Previous therapy with standard alpha-interferon or peginterferon will not exclude patients.
  7. Patients who are HBV therapy-naïve or who previously received HBV antiviral therapy will be eligible. Patients currently taking HBV antiviral therapy will e considered on a case basis.
  8. Female subjects of reproductive potential and female partners of male subjects should be on two reliable forms of contraception from the start of the study until 60 days from the end of EBP921 dosing.

Exclusion Criteria:

  1. Severe neuropsychiatric disorders
  2. History or clinical manifestations of significant metabolic, hematological, pulmonary, ischemic heart disease, significant or unstable heart disease, gastrointestinal, neurological, renal, urological, endocrine, ophthalmologic disorders including severe retinopathy, or immune-mediated disease
  3. Pregnant or breast-feeding patients or the inability to practice adequate contraception during the conduct of the study
  4. Underlying autoimmune/immune-deficiency disease (e.g., lupus, sarcoidosis, celiac disease, HIV antibody positive, AIDS)
  5. Chronic (> 4 weeks duration) diarrhea
  6. Body weight > 128 kg and < 40 kg
  7. Uncompensated cirrhosis
  8. Absolute neutrophil count less than 1500 per cubic millimeter
  9. Platelet count less than 90,000 per cubic millimeter
  10. Evidence of concurrent HCV infection with positive serum HCVRNA
  11. Evidence of hepatocellular carcinoma
  12. Active substance abuse (alcohol, inhaled or injected drugs) within the past 12 months
  13. Diagnosis of malignancy in the previous five years excluding superficial dermatologic malignancies
  14. Any experimental therapy in the previous 6 months prior to enrollment.

16. Patients with a history of multiple drug resistant HBV 17. Patients receiving interferon therapy for any reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01316185

Layout table for location information
United States, California
San Francisco, California, United States
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Sponsors and Collaborators
Eiger BioPharmaceuticals
Layout table for investigator information
Study Director: Brian Murphy, MD, MPH Eiger BioPharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Eiger BioPharmaceuticals Identifier: NCT01316185    
Other Study ID Numbers: EBP-HDV 01-921-01
First Posted: March 16, 2011    Key Record Dates
Last Update Posted: August 8, 2016
Last Verified: August 2016
Keywords provided by Eiger BioPharmaceuticals:
Hepatitis D
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis D
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections